Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Clinical and experimental evidence suggest that interleukin-17A (IL-17A; also known as IL-17) is an attractive therapeutic target in rheumatoid arthritis (RA). Rheumatoid synovial tissue produces IL-17A, which causes cartilage and bone degradation in synovial and bone explants. Overexpression of IL-17A induces synovial inflammation and joint destruction in animal RA models. These effects are attenuated in IL-17A-deficient animals and by agents that block IL-17A. Serum IL-17A levels and, to a greater extent, synovial fluid IL-17A levels are elevated in many patients with RA. In some RA cohorts, higher IL-17A levels have been associated with a more severe clinical course. Several IL-17A blockers, including the anti-IL-17A monoclonal antibodies secukinumab and ixekizumab, and the anti-IL-17 receptor subunit A monoclonal antibody brodalumab have been evaluated in phase II clinical trials. Of these, secukinumab is the most advanced with respect to clinical evaluation in RA, with phase III trials ongoing in patients on background methotrexate who had inadequate responses to previous tumor necrosis factor blocker therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514 · cited 2×
“2009; McInnes and Schett, 2011; Zhang and Anis, 2011].”
BackgroundKorn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873 · cited 1×
“T-helper-17 cell differentiation Differentiation of Th17 cells from naïve clusterof-differentiation (CD)-4-positive T cells is mediated by different cytokines and transcription factors than those involved in differentiation of other Th-cell lineages [Korn et al. 2009; Miossec et al. 2009].”
BackgroundA distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265 · cited 2×
“The next major advance came in 2005 when IL-17A was shown to be produced by a new lineage of Th cells, termed Th17, which arise via a distinct pathway from the Th1 and Th2 subsets [Harrington et al. 2005; Park et al. 2005].”
BackgroundIL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 2×
“Importantly, Th17 cells were shown to be essential for the development of autoimmune inflammation in animal models [Langrish et al. 2005].”
BackgroundAcosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A., & Sallusto, F. (2007) · Nature Immunology · doi:10.1038/ni1496 · Cited by 1,857 · cited 1×
“In human CD4-positive cells, IL-1β plus either IL-23 or IL-6 are needed to induce RORc, the human counterpart of RORγt, leading to Th17 commitment [Acosta-Rodriguez et al. 2007; Annunziato and Romagnani, 2009; Wilson et al. 2007].”
BackgroundSato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., Tanaka, S., Kodama, T., Akira, S., Iwakura, Y., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061775 · Cited by 1,554
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475 · cited 3×
“The other IL-17 family members have poorly characterized proinflammatory properties, but do not interact with receptors containing the IL-17RA subunit [Gaffen, 2009; Pappu et al.”
BackgroundInterleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409 · cited 2×
“Safety considerations Despite the extensive rationale for targeting IL-17A, it is important to remember that this cytokine is the principal effector of Th17 cells and, therefore, plays an important role in host defense against extracellular bacteria and fungi at mucosal surfaces [Miossec et al. 2009; Onishi and Gaffen…”
BackgroundFunctional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Cited by
Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells
Jang, S., Kwon, E.-J., & Lee, J. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020905 · Cited by 612
Regulation of Osteoclast Differentiation by Cytokine Networks
Amarasekara, D. S., Yun, H., Kim, S., Lee, N., Kim, H., & Rho, J. (2018) · Immune Network · doi:10.4110/in.2018.18.e8 · Cited by 518
“Anti-IL-17 therapies, such as secukinumab, ixekizumab, and brodalumab, have been undergoing clinical trials (61).”
Basic biology and role of interleukin‐17 in immunity and inflammation
Zenobia, C., & Hajishengallis, G. (2015) · Periodontology 2000 · doi:10.1111/prd.12083 · Cited by 470
T cell migration in rheumatoid arthritis
Mellado, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00384 · Cited by 291
Pineda, M. A., Lumb, F., Harnett, M. M., & Harnett, W. (2014) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2014.03.003 · Cited by 88
Metadata
- Authors
- Kellner, H.
- Venue
- Therapeutic Advances in Musculoskeletal Disease
- Publisher
- SAGE Publications
- Published
- 2013-05-23
- Volume
- 5
- Issue
- 3
- Pages
- 141-152
- ISSN
- 1759-720X (ISSN-L)
- 1759-7218
- OpenAlex
- W2116633865
- Cited by
- 109
- References
- 14
- FWCI
- 13.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. https://app.cochat.ai/papers/10.1177/1759720x13485328
- The paper
- Kellner, H. (2013). Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Therapeutic Advances in Musculoskeletal Disease. https://doi.org/10.1177/1759720x13485328
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.